Help me answer these two questions please!

1) Briefly describe the clinical problem being addressed by the research.

2)What type of study method did the researchers use? Describe some of the design features of the study that you think are important to understand. (No need to cover every detail of the article - and there can be multiple correct answers to this part).

BACKGROUND On the basis of the 2014 guidelines for hypertension therapy in the United States, From the Coll many eligible adults remain untreated. We projected the cost-effectiveness of treat- geons, Columb ing hypertension in U.S. adults according to the 2014 guidelines. and Division of bia University A.T., K.Y.T., P.W METHODS School of Bi We used the Cardiovascular Disease Policy Model to simulate drug-treatment and Health Science monitoring costs, costs averted for the treatment of cardiovascular disease, and Corvallis (M.C. cine, Universit quality-adjusted life-years (QALYs) gained by treating previously untreated adults cisco (D.G., K.B between the ages of 35 and 74 years from 2014 through 2024. We assessed cost- Health Care, B effectiveness according to age, hypertension level, and the presence or absence of print requests University Divi chronic kidney disease or diabetes. Presbyterian 105, 622 West RESULTS 10032, or at ae The full implementation of the new hypertension guidelines would result in ap- This article was proximately 56,000 fewer cardiovascular events and 13,000 fewer deaths from car- at NEJM.org. diovascular causes annually, which would result in overall cost savings. The project N Engl) Med 201 tions showed that the treatment of patients with existing cardiovascular disease or DOI: 10.1056/NE stage 2 hypertension would save lives and costs for men between the ages of 35 and Copyright @ 2015 74 years and for women between the ages of 45 and 74 years. The treatment of men or women with existing cardiovascular disease or men with stage 2 hypertension but without cardiovascular disease would remain cost-saving even if strategies to increase medication adherence doubled treatment costs. The treatment of stage 1 hypertension was cost-effective (defined as